Open AccessHyperammonemic encephalopathy in a patient receiving fluorouracil/oxaliplatin chemotherapy
Author(s) -
Ihoriya Hiromi,
Yamamoto Hirotsugu,
Yamada Taihei,
Tsukahara Kohei,
Inoue Kanae,
Yumoto Tetsuya,
Naito Hiromichi,
Nakao Atsunori
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1422
Subject(s) - medicine , oxaliplatin , hyperammonemia , adverse effect , encephalopathy , fluorouracil , chemotherapy , intensive care medicine , pediatrics , colorectal cancer , cancer
Key Clinical Message Hyperammonemia is a rare adverse effect of 5‐fluorouracil (5‐ FU ) therapy, but can be very serious, even fatal. Physicians must be aware that hyperammonemic encephalopathy sometimes develops as an adverse event after 5‐ FU therapy.